Merck Sharp & Dohme Corp. - Recruiting 18 years or older. - A Phase Ib Randomized, Double-Blinded, Placebo-Controlled Multiple Rising Dose Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MK-8226 in Patients With Moderate to Severe Atopic Dermatitis.
Sterna Biologicals GmbH & Co. KG - Recruiting 18 years to 60 years. - A Phase IIa, Single-centre, Randomised, Vehicle Controlled, Double-blind Trial for Assessment of Efficacy, Safety and Tolerability of the Topical Formulation SB011 Containing a Human GATA-3 Specific DNAzyme and of Systemic Absorption of hgd40 Following Application to Lesional Skin in Patients With Atopic Eczema.
SB011, 2 % (Water/Oil/Water) emulsion of hgd40; Multiple W/O/W formulation, active ingredient-free vehicle
Pfizer - Recruiting 18 years to 50 years. - A Phase 2a, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis.
Janssen Pharmaceutical K.K. - Recruiting 20 years to 65 years. - A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis.
Ustekinumab; Placebo; Concomitant topical medications for atopic dermatitis
Kang Stem Holdings Co., Ltd. - Recruiting 20 years to 60 years. - Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis.
Bayer - Recruiting 18 years to 60 years. - An Investigator-blinded, Randomized, Monocentre, 3-arm, Pilot Trial to Compare the Efficacy and Safety of Two Topical Medical Devices in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With Untreated Skin.
Rockefeller University - Recruiting 18 years to 75 years. - Phase II Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) in Subjects With Atopic Dermatitis (AD).
Regeneron Pharmaceuticals - Recruiting 18 years or older. - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis.
Atopix Therapeutics, Ltd. - Recruiting 18 years to 40 years. - A Study of the Effect of OC000459 on Signs and Symptoms in Subjects With Moderate to Severe Atopic Dermatitis: A Randomised Double Blind Placebo Controlled Parallel Group Study.
LEO Pharma - Recruiting 18 years to 65 years. - A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream.
TopMD Skin Care, Inc. - Recruiting 18 years or older. - A Double-Blind Pilot Study To Assess The Feasibility of a Larger Study to Assess The Efficacy of A Novel Gel Wash Cleanser Formulated With Sodium Hypochlorite To Reduce Skin Fauna In Patients With Chronic Hand Dermatitis/Atopic Dermatitis..
University of Texas Southwestern Medical Center - Recruiting 2 years to 17 years. - A Randomized, Controlled, Evaluator-blinded Study to Evaluate the Efficacy of Dilute Bleach Baths on Skin Disease Control in Pediatric Patients With Atopic Dermatitis.